Abcellera Biologics Inc (ABCL) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ABCL Annual Balance Sheets →
The balance sheet figures below highlight longer-term patterns in how Abcellera Biologics Inc finances operations and invests in assets.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Available-for-sale Securities, Debt Securities MA427.67
Cash & Short-term Investments427.00
Other Current Assets159.86
Total Current Assets664.60
Goodwill net47.81
Intangible Assets37.46
Long-term investments65.31
Other Assets, Noncurrent557.25
Accounts And Accrued Receivable Current36.76
Total Assets1,307.11
Liabilities
Accounts Payable and Other Accrued Liabilities, Current39.55
Business Combination, Contingent Consideration, Liability, Current BU0.00
Total Current Liabilities47.29
Total Long-term Debt0.00
Other liabilities, Noncurrent321.74
Contract With Customer Liability Current7.74
Operating Lease Liability Noncurrent134.31
Deferred Income Tax Liabilities Net-
Total Liabilities369.03
Stockholders' Equity
Common Stock Value816.53
Additional Paid In Capital Common Stock196.62
Retained Earnings / Accumulated Deficit-72.65
Other Equity-2.42
Common Stockholder's Equity938.08
Total Stockholder's Equity938.08
Liabilities & Stockholder's Equity1,307.11
4 historic quarters locked

Sign in to unlock the full Abcellera Biologics Inc balance sheet history.

About Abcellera Biologics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001703057-26-000046

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.